Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain

Journal of Pain and Symptom Management

Volumn 40, Issue 5, 2010, Pages 734-746

  Webster, Lynn R ^a   Brewer, Randall ^b   Wang, Chao ^c   Sekora, Doreen ^c   Johnson, Franklin K ^c   Morris, David ^d   Stauffer, Joseph ^c,e  

^a Lifetree Clinical Research and Pain Clinic   (United States)

^b Willis Knighton Health System   (United States)

^c Alpharma Pharmaceuticals   (United States)

^d WebbWrites   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic pain; Morphine; Naltrexone; Opioid

Indexed keywords

EMBEDA; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; NALTREXONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC PAIN; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRURITUS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT REFUSAL; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NAUSEA; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 78349272369     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.05.004     Document Type: Article

References (44)

1. American Pain Society Chronic pain in America: roadblocks to relief. American Pain Society Available from http://www.ampainsoc.org/links/roadblocks/ conclude-road.htm 2008 Accessed October 9, 2009
2. P. Sloan, and N. Babul Extended-release opioids for the management of chronic non-malignant pain Expert Opin Drug Deliv 3 2006 489 497
3. A.D. Woolf, and B. Pfleger Burden of major musculoskeletal conditions Bull World Health Organ 81 2003 646 656
4. B.H. McCarberg, B.D. Nicholson, K.H. Todd, T. Palmer, and L. Penles The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey Am J Ther 15 2008 312 320
5. American Pain Society The use of opioids for the treatment of chronic pain: a consensus statement from American Academy of Pain Medicine and American Pain Society. American Pain Society Available from http://www.ampainsoc.org/ advocacy/opioids.htm 2005 Accessed May 10, 2005
6. R. Chou, G.J. Fanciullo, and P.G. Fine Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain J Pain 10 2009 113 130
7. K.M. Jordan, N.K. Arden, and M. Doherty EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis 62 2003 1145 1155
8. AGS Panel on Persistent Pain in Older Persons The management of persistent pain in older persons J Am Geriatr Soc 50 6 Suppl 2002 S205 S224
9. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee Arthritis Rheum 43 2000 1905 1915
10. A.M. Trescot, S. Helm, and H. Hansen Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines Pain Physician 11 2008 S5 S62
11. J.C. Ballantyne, and J. Mao Opioid therapy for chronic pain N Engl J Med 349 2003 1943 1953
12. B.H. McCarberg, and R.L. Barkin Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia Am J Ther 8 2001 181 186
13. B. Nicholson Responsible prescribing of opioids for the management of chronic pain Drugs 63 2003 17 32
14. A. Gibofsky, and R.L. Barkin Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic Am J Ther 15 2008 241 245
15. J.A. Markenson, J. Croft, P.G. Zhang, and P. Richards Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial Clin J Pain 21 2005 524 535
16. L. Manchikanti National drug control policy and prescription drug abuse: facts and fallacies Pain Physician 10 2007 399 424
17. A.M. Gagnon, M. Kahan, and A. Srivastava Opioid use and abuse: is there a problem? Clin J Pain 23 2007 661 662
18. B.M. Kuehn Opioid prescriptions soar: increase in legitimate use as well as abuse JAMA 297 2007 249 251
19. N.P. Katz, E.H. Adams, and J.C. Benneyan Foundations of opioid risk management Clin J Pain 23 2007 103 118
20. F.K. Johnson, J.G. Stark, F.A. Bieberdorf, and J. Stauffer Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers Clin Ther 32 2010 1149 1164
21. J. Stauffer, B. Setnik, and M. Sokolowska Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study Clin Drug Invest 29 2009 777 790
22. N.P. Katz, S. Sun, F.K. Johnson, and J. Stauffer ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety J Pain 11 2010 303 311
23. J.B. Jones, L. Fox, N. Katz, D. Morris, and J. Stauffer Efficacy and tolerability of ALO-01 (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules in patients with chronic moderate-to-severe pain from osteoarthritis of the hip or knee [poster 238] Arch Phys Med Rehabil 89 2008 e97
24. E.L. Ross, and K. Hahn KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain Int J Clin Pract 62 2008 471 479
25. D.R. Wesson, and W. Ling The Clinical Opiate Withdrawal Scale (COWS) J Psychoactive Drugs 35 2003 253 259
26. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
27. Pr REVIA™ (naltrexone hydrochloride), Tablets 50 mg Opioid Antagonist. Weston, Ontario, Canada: Apotex Inc; May 9, 2003. Control No. 084148.
28. ® 2007 Barr Pharmaceuticals, Inc. Montvale, NJ [package insert]
29. K. Verebey The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics R.E. Willette, G. Barnett, Narcotic antagonists: Naltrexone pharmacochemistry and sustained release preparations 1980 US Department of Health and Human Services Rockville, MD 147 158 NIDA Research Monograph 28. DHHS publication (ADM) 81-92
30. M.H. Slawson, M. Chen, and S.D. Comer Quantitative analysis of naltrexone and 6beta-naltrexol in human, rat, and rabbit plasma by liquid chromatograpy-electrospray ionization tandem mass spectrometry with application to the pharmacokinetics of Depotrex in rabbits J Anal Toxicol 31 2007 453 461
31. W.M.D.E. Huang, R.L. Foltz, and S.L. Walsh Determination of naltrexone and 6-beta-naltrexol in plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry J Anal Toxicol 21 1997 252 257
32. M.C. Meyer, A.B. Straughn, M.W. Lo, W.L. Schary, and C.C. Whitney Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration J Clin Psychiatry 45 9 Pt 2 1984 15 19
33. A.L. Misra Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone R.E. Willette, G. Barnett, Narcotic antagonists: Naltrexone pharmacochemistry and sustained-release preparations 1981 US Department of Health and Human Services Rockville, MD 132 146 NIDA Research Monograph 28. DHHS publication (ADM) 81-92
34. Wong DF, Ye W, Zhou Y, et al. In vivo human opiate receptor occupancy of naltrexone: a dose-response analysis. Abstract presented from: The Society for Neuroscience conference. 2006. Available from http://cms.sfn.org/index.aspx? pagename=abstracts-ampublications. Accessed September 10, 2010.
35. R.K. Portenoy, J.T. Farrar, and M.M. Backonja Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study Clin J Pain 23 2007 287 299
36. J.C. Ballantyne Opioid analgesia: perspectives on right use and utility Pain Physician 10 2007 479 491
37. L.G. Allan, U. Rucharz, K. Simpson, and R. Slappendel Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain Spine 30 2005 2484 2490
38. P.L. Dellemijn, H. van Duijn, and J.A. Vanneste Prolonged treatment with transdermal fentanyl in neuropathic pain J Pain Symptom Manage 16 1998 220 229
39. K. Milligan, M. Lanteri-Minet, and K. Borchert Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic non-cancer pain J Pain 2 2001 197 204
40. B. Nicholson, E. Ross, J. Sasaki, and A. Weil Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain Curr Med Res Opin 22 2006 1503 1514
41. S.H. Roth, R.M. Fleischmann, and F.X. Burch Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation Arch Intern Med 160 2000 853 860
42. M. Wallace, D.E. Moulin, and R.L. Rauck Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain J Opioid Manage 5 2009 97 105
43. J.R. Caldwell, R.J. Rapoport, and J.C. Davis Efficacy and safety of once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label trial J Pain Symptom Manage 23 2002 278 291
44. M. Noble, S.J. Tregear, J.R. Treadwell, and K. Schoelles Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety J Pain Symptom Manage 35 2008 214 228